08:41 AM EDT, 03/19/2026 (MT Newswires) -- Biohaven ( BHVN ) said Thursday that it has completed enrollment for a phase 2 proof-of-concept study evaluating treatment with once-weekly and once-monthly taldefgrobep alfa in people living with obesity.

The primary outcome measure of the study is percent change in total body weight from baseline to week 24, and secondary outcome measures are percent change in total body fat mass and in total body lean mass, the company said.

Topline data from the study is expected in H2, according to Biohaven ( BHVN ).

The phase 2 study is a double-blind, placebo-controlled, dose-ranging trial with about 150 participants for randomization, the company added.